NCAA Cannabis Policy 2026: D-I Removed, D-II/III Pending
NCAA Division I removed cannabinoids from championship/postseason testing on June 25, 2024. Per-school discretion remains, D-II/III rules pending. Past-year use up to 26% (2022-23).
Status: D-I Removed; D-II/III Pending Removed from list
The June 25, 2024 vote of the NCAA Division I Council to remove cannabinoids from championship and postseason football testing — applied retroactively to existing penalties — was the largest collegiate-sports policy reform on cannabis in 38 years. Through May 2026, Divisions II and III have not yet adopted parallel rules, though the CSMAS (Committee on Competitive Safeguards and Medical Aspects of Sports) recommendation that triggered the D-I action applies to all three divisions.
NCAA Cannabis Testing Chronology
- 1986 — NCAA drug-testing program established. Cannabis threshold 15 ng/mL; positive test = full-season suspension.
- 2013 — Threshold lowered to 5 ng/mL; penalty reduced to half-season.
- 2017 — Threshold raised back to 15 ng/mL.
- 2019 — Threshold raised to 35 ng/mL.
- February 2022 — Threshold raised to 150 ng/mL by CSMAS, aligning with the WADA standard.
- September 2023 — CSMAS recommended eliminating cannabis testing across all three divisions.
- June 25, 2024 — NCAA Division I Council voted to remove cannabinoids from championship/postseason football testing, effective immediately and applied retroactively.
- 2024–present — Divisions II and III considering parallel adoption.
The June 25, 2024 D-I Council Vote
NCAA Division I Council chair Josh Whitman (University of Illinois Athletic Director) framed the decision in performance-integrity terms: "The NCAA drug testing program is intended to focus on integrity of competition, and cannabis products do not provide a competitive advantage."
CSMAS vice chair Deena Casiero (UConn head team physician) had said the previous year, in setting up the recommendation: "We know that the previous cannabinoid policies and sanctions were not an effective deterrent to cannabinoid use… Randomly testing at NCAA championships is not the best way to identify or help student-athletes with use issues."
The retroactive application meant student-athletes serving cannabis-related suspensions at the time of the vote had those penalties eliminated. The decision deliberately framed the change as a Substance Use matter rather than a Performance Enhancement matter — a distinction that mirrors MLB's December 2019 framing and the conclusion of the December 2022 NCAA Cannabinoid Summit.
NCAA Substance Use Survey: Prevalence Trends
The NCAA Student-Athlete Substance Use Study has been the single best longitudinal dataset on athlete cannabis use in the United States, conducted in 1985, 1989, 1993, 1997, 2001, 2005, 2009, 2013, 2017, and most recently as the 2022–2023 NCAA Student-Athlete Health and Wellness Study (results released January 2024 from a representative sample of 23,272 student-athletes). Past-year cannabis use:
- 2013 — 22%.
- 2017 — 25%.
- 2022–2023 — 26%.
Use is highest in Division III, in men's sports, and in legal-cannabis states. NCAA student-athlete prevalence sits below general college-population estimates of approximately 38% (American College Health Association NCHA-III, Spring 2023) and 41% (Monitoring the Future Panel Study, 2022). Older NCAA waves had reported past-year prevalence at 28.4% (Green et al., Clinical Journal of Sport Medicine, 2001) and figures rising to 38% in a 2009 wave — illustrating the often-cited 24%-to-43% NCAA range across decades of sampling.
Per-School Discretion + State Law Overlay
The June 2024 D-I removal applies only to championship and postseason football testing run by the NCAA itself. Schools retain authority to test during the regular season, with school-specific penalty structures. State law layers on top of that:
- In legal-rec states (CA, CO, MA, NY, IL, MI, etc.), schools have largely tolerated.
- In prohibitionist states (TX, TN, KS, ID, etc.), school policies are typically more punitive.
The result is a patchwork that produces the same conduct receiving wildly different consequences depending on the institution and state. See College Athletes & Cannabis for the practical implications.
Title IX and Equity
Disparate enforcement of cannabis testing by gender and race has been raised in legal commentary — notably Vande Streek's analysis in the Marquette Sports Law Review (2022). NCAA-published racial breakdowns of historic suspensions are limited, and Limited evidence rigorous prevalence-by-race data for athletes is not yet published. The Title IX equity question is independent of the rec-vs-prohibition state-law issue: even within a single school, cannabis-testing enforcement patterns may produce gender or racial disparities that the Title IX framework should reach.
NIL and Cannabis Brand Deals
Post-2021 NIL liberalization opened the door to athlete cannabis brand deals — but federal hemp-cliff timing, state-law conflicts, and remaining school-level testing make this a fraught area. The Big Ten in particular has school policies discouraging cannabis-brand NIL agreements. For the federal hemp framework that landed November 12, 2026, see Federal Hemp Cliff.
"Substance Use" vs "Performance Enhancement"
The NCAA's June 2024 framing explicitly classifies cannabis as a Substance Use matter, not a Performance Enhancement matter — paralleling MLB's December 2019 alcohol-equivalent treatment (see MLB Cannabis Policy). The NCAA Cannabinoid Summit in December 2022 had reached the same consensus. The framing matters for resource allocation: testing dollars and discipline mechanisms get redirected toward genuinely performance-enhancing substances (anabolic steroids, EPO, hormones), while cannabis questions get routed into clinical and educational pathways.